Immunoglobulin E and bullous pemphigoid

Eur J Dermatol. 2018 Aug 1;28(4):440-448. doi: 10.1684/ejd.2018.3366.

Abstract

Clinical features and histological findings in bullous pemphigoid (BP) suggest a Th2-oriented inflammatory reaction, especially in the early stages of the disease. Elevated total serum IgE levels, blood eosinophilia, and elevated serum levels of different soluble inflammatory Th2 response mediators have been described in large cohorts of patients with classic clear-cut BP manifestations. Direct immunofluorescence, indirect immunofluorescence, and anti-BP230 and anti-BP180 IgE ELISA testing show self-reactive IgE autoantibodies in a consistent number of BP patients. Both IgE autoantibodies and a Th2-oriented immune response may play a role in the initial phases of BP and atypical cases of BP, such as severe erythematous and urticarial forms of BP, as well as blister formation. Two recently reported experimental murine models employing IgE autoantibodies against BP180 have been reported and the successful treatment of bullous pemphigoid with the anti-IgE antibody, omalizumab, supports the roles played by IgE autoantibodies in BP pathogenesis.

Keywords: Th2; anti-BP230 and anti-BP180 IgE; bullous pemphigoid; omalizumab.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Allergic Agents / therapeutic use
  • Autoantibodies / blood*
  • Autoantigens / immunology
  • Collagen Type XVII
  • Dystonin / immunology
  • Eosinophilia / blood
  • Humans
  • Immunoglobulin E / blood*
  • Non-Fibrillar Collagens / immunology
  • Omalizumab / therapeutic use
  • Pemphigoid, Bullous / blood*
  • Pemphigoid, Bullous / drug therapy
  • Pemphigoid, Bullous / immunology*
  • Pemphigoid, Bullous / pathology
  • Th2 Cells / immunology*

Substances

  • Anti-Allergic Agents
  • Autoantibodies
  • Autoantigens
  • Dystonin
  • Non-Fibrillar Collagens
  • Omalizumab
  • Immunoglobulin E